A detailed history of Geode Capital Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,374,697 shares of PTGX stock, worth $56.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,374,697
Previous 1,371,169 0.26%
Holding current value
$56.4 Million
Previous $47.5 Million 30.03%
% of portfolio
0.01%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$33.72 - $47.33 $118,964 - $166,980
3,528 Added 0.26%
1,374,697 $61.8 Million
Q2 2024

Aug 09, 2024

BUY
$24.66 - $34.8 $1.91 Million - $2.69 Million
77,430 Added 5.98%
1,371,169 $47.5 Million
Q1 2024

May 13, 2024

BUY
$21.79 - $32.15 $990,464 - $1.46 Million
45,455 Added 3.64%
1,293,739 $37.4 Million
Q4 2023

Feb 13, 2024

BUY
$14.05 - $23.44 $941,743 - $1.57 Million
67,028 Added 5.67%
1,248,284 $28.6 Million
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $1.74 Million - $2.46 Million
104,072 Added 9.66%
1,181,256 $19.7 Million
Q2 2023

Aug 11, 2023

BUY
$18.02 - $29.36 $2.72 Million - $4.44 Million
151,191 Added 16.33%
1,077,184 $29.8 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $496,979 - $1.17 Million
46,102 Added 5.24%
925,993 $21.3 Million
Q4 2022

Feb 13, 2023

BUY
$7.36 - $11.17 $385,921 - $585,698
52,435 Added 6.34%
879,891 $9.6 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $43,505 - $64,814
5,535 Added 0.67%
827,456 $6.98 Million
Q2 2022

Aug 12, 2022

SELL
$7.06 - $25.52 $77,660 - $280,720
-11,000 Reduced 1.32%
821,921 $6.5 Million
Q1 2022

May 13, 2022

BUY
$23.34 - $36.08 $1.28 Million - $1.98 Million
54,840 Added 7.05%
832,921 $19.7 Million
Q4 2021

Feb 11, 2022

BUY
$17.63 - $37.1 $866,532 - $1.82 Million
49,151 Added 6.74%
778,081 $26.6 Million
Q3 2021

Nov 12, 2021

BUY
$12.95 - $49.69 $195,441 - $749,921
15,092 Added 2.11%
728,930 $12.9 Million
Q2 2021

Aug 13, 2021

BUY
$25.57 - $44.88 $1.74 Million - $3.06 Million
68,159 Added 10.56%
713,838 $32 Million
Q1 2021

May 12, 2021

BUY
$19.02 - $31.15 $2.61 Million - $4.28 Million
137,378 Added 27.03%
645,679 $16.7 Million
Q4 2020

Feb 12, 2021

BUY
$18.49 - $25.13 $1.28 Million - $1.74 Million
69,187 Added 15.76%
508,301 $10.2 Million
Q3 2020

Nov 13, 2020

BUY
$15.19 - $22.4 $1.07 Million - $1.58 Million
70,744 Added 19.2%
439,114 $8.58 Million
Q2 2020

Aug 13, 2020

BUY
$6.19 - $18.84 $462,851 - $1.41 Million
74,774 Added 25.47%
368,370 $6.51 Million
Q1 2020

May 14, 2020

BUY
$5.4 - $9.22 $124,189 - $212,041
22,998 Added 8.5%
293,596 $2.07 Million
Q4 2019

Feb 13, 2020

BUY
$4.69 - $13.45 $44,203 - $126,766
9,425 Added 3.61%
270,598 $1.91 Million
Q3 2019

Nov 12, 2019

BUY
$9.41 - $16.56 $539,400 - $949,252
57,322 Added 28.12%
261,173 $3.14 Million
Q2 2019

Aug 14, 2019

BUY
$8.98 - $12.96 $639,438 - $922,842
71,207 Added 53.68%
203,851 $2.47 Million
Q1 2019

May 14, 2019

BUY
$6.5 - $13.77 $97,155 - $205,820
14,947 Added 12.7%
132,644 $1.67 Million
Q4 2018

Feb 13, 2019

SELL
$6.3 - $10.44 $806 - $1,336
-128 Reduced 0.11%
117,697 $792,000
Q3 2018

Nov 13, 2018

SELL
$6.82 - $11.26 $55,937 - $92,354
-8,202 Reduced 6.51%
117,825 $1.21 Million
Q2 2018

Aug 14, 2018

SELL
$5.99 - $9.1 $93,785 - $142,478
-15,657 Reduced 11.05%
126,027 $846,000
Q1 2018

May 15, 2018

BUY
$8.46 - $23.08 $14,441 - $39,397
1,707 Added 1.22%
141,684 $1.22 Million
Q4 2017

Feb 13, 2018

BUY
$14.47 - $20.8 $392,643 - $564,408
27,135 Added 24.05%
139,977 $2.91 Million
Q3 2017

Nov 14, 2017

BUY
$10.61 - $17.98 $63,256 - $107,196
5,962 Added 5.58%
112,842 $1.99 Million
Q2 2017

Aug 14, 2017

BUY
N/A
106,880
106,880 $1.21 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.01B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.